We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

SphingoTec Logo


SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Their aspiration is to translate scientific advancements into routine clinical practice effectively. They develop biomarkers addressing diagnostically underserved critical care conditions such as acute kidney injury, sepsis and acute heart failure. First and foremost, their portfolio of tests supports better management of critically ill patients, where fast and reliable information is of the essence in taking treatment decisions.